Evidence map›Paper›PMID 39081794›Full record

ArticleFrontiers in endocrinology2024

Thyroid dysfunction in the wake of Omicron: understanding its role in COVID-19 severity and mortality.

Qingfeng Zhang, Zongyue Zhang, Xu Liu, Yixuan Wang, Hao Chen, Yueying Hao, Shiqian Zha, Jingyi Zhang, Yang He, Beini Zhou and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Qingfeng Zhang *Department of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, China.
Zongyue Zhang *Department of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, China.
Xu LiuDepartment of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, China.
Yixuan WangDepartment of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, China.
Hao ChenDepartment of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, China.
Yueying HaoDepartment of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, China.
Shiqian ZhaDepartment of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, China.
Jingyi ZhangDepartment of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, China.
Yang HeDepartment of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, China.
Beini ZhouDepartment of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, China.
Ke HuDepartment of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: SARS-CoV-2 can invade the thyroid gland. This study was to delineate the risk of thyroid dysfunction amidst the prevalence of the Omicron variant, and to investigate the correlation between thyroid function and Coronavirus disease 2019 (COVID-19) outcomes. The study also aimed to ascertain whether thyroid dysfunction persisted during COVID-19 recovery phase. Methods: This was a retrospective cohort study. COVID-19 patients from the Renmin Hospital of Wuhan University, China during the epidemic of Omicron variants were included, and their thyroid function were analyzed in groups. Results: A history of thyroid disease was not associated with COVID-19 outcomes. COVID-19 can lead to a bimodal distribution of thyroid dysfunction. The severity of COVID-19 was inversely proportional to the levels of thyroid- stimulating hormone (TSH), free triiodothyronine (FT3) and free thyroxine (FT4), leading to a higher prevalence of thyroid dysfunction. Severe COVID-19 was a risk factor for euthyroid sick syndrome (ESS) (OR=22.5, 95% CI, 12.1 - 45.6). Neutrophil to lymphocyte ratio mediated the association between severe COVID-19 and ESS (mediation effect ratio = 41.3%, p < 0.001). ESS and decreased indicators of thyroid function were associated with COVID-19 mortality, while high levels of FT3 and FT4 exhibited a protective effect against death. This effect was more significant in women (p < 0.05). During the recovery period, hyperthyroidism was quite uncommon, while a small percentage of individuals (7.7%) continued to exhibit hypothyroidism. Conclusion: COVID-19 severity was linked to thyroid dysfunction. Severe COVID-19 increased the risk of ESS, which was associated with COVID-19 mortality. Post-recovery, hyperthyroidism was rare, but some individuals continued to have hypothyroidism.

Indexed as

COVID-19SARS-CoV-2Severity of Illness IndexThyroid DiseasesAdultAgedChinaEuthyroid Sick SyndromesFemaleHumansMaleMiddle AgedPandemicsRetrospective StudiesRisk FactorsThyroid Function TestsThyrotropinThyroxineTriiodothyronineCOVID-19euthyroid sick syndromehyperthyroidismhypothyroidismOmicron variantthyroid dysfunction

Identifiers

PMID39081794
PMCPMC11286428

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.